| Balance Sheets | 2025-07-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 334 | |||
| Accounts receivable | 474 | |||
| Inventories, net | 141 | |||
| Restricted cash | 75 | |||
| Prepaid expenses | 23 | |||
| Total current assets | 1,047 | |||
| Property, plant and equipment, net | 11 | |||
| Total assets | 1,058 | |||
| Accounts payable | 784 | |||
| Accrued liabilities | 154 | |||
| Total current liabilities | 938 | |||
| Convertible notes payable to related parties-Related Party | 5,236 | |||
| Total liabilities | 6,174 | |||
| Common stock, 0.01 par value 200,000,000 shares authorized, 111,886,473 shares issued and outstanding at july 31, 2025, and 111,856,473 shares issued and outstanding at july 31, 2024 | 1,119 | |||
| Additional paid-in capital | 132,759 | |||
| Accumulated deficit | -138,994 | |||
| Total stockholders deficiency | -5,116 | |||
| Total liabilities and stockholders deficiency | 1,058 | |||
PURE BIOSCIENCE, INC. (PURE)
PURE BIOSCIENCE, INC. (PURE)